As pragmatically stated by Revuelta and Lippa[20] in 2009, “DLB and PDD are one entity when therapies are developed that influence pathological alpha‐synuclein protein aggregation and other common biological alterations.” The gene discussed is SNCA; the disease is Lewy body dementia.